| |
Figure 2. Strategies for designing vaccines for severe acute respiratory
syndrome (SARS) using A) spike (S) protein and B) fragments containing
neutralizing epitopes. SP, signal peptide; RBD, receptor binding domain;
FP, fusion peptide; HR, heptad repeat; TM, transmembrane domain; CP, cytoplasm
domain. IDS, immunodominant sites I to V corresponding to the sequences
of amino acid residues 9–71, 171–224, 271–318, 528–635, and 842–913, respectively.
The residue numbers of each region correspond to their positions in the
S protein of SARS–associated coronavirus (SARS-CoV) strain Tor2. RBD contains
the major neutralizing epitopes in the S protein. The recombinant RBD
may be used as an efficacious and safe vaccine for preventing infection
by SARS-CoV strains with distinct genotypes.
|
